找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Oral Pharmacotherapy for Male Sexual Dysfunction; A Guide to Clinical Gregory A. Broderick Book 2005 Humana Press 2005 Internist.assessmen

[復(fù)制鏈接]
樓主: Coenzyme
41#
發(fā)表于 2025-3-28 14:56:57 | 只看該作者
Physiology and Pharmacology of Erectile Dysfunction,al-generated NO, in that the latter essentially helps in maintaining penile erection. Moreover, the role of endothelium in regulating smooth muscle tone and the intercellular link by means of gap junctions have also been uncovered. More recently, research has shown that changes to the downstream sig
42#
發(fā)表于 2025-3-28 19:00:16 | 只看該作者
43#
發(fā)表于 2025-3-28 22:55:26 | 只看該作者
44#
發(fā)表于 2025-3-29 06:51:19 | 只看該作者
45#
發(fā)表于 2025-3-29 07:28:14 | 只看該作者
When to Refer the Patient With Erectile Dysfunction to a Specialist,gists. Now, as primary care physicians have become increasingly sophisticated in their knowledge of ED, they, along with their nurse practitioners and physician’s assistants, account for about two-thirds of prescriptions written for phosphodiesterase (PDE) inhibitors.
46#
發(fā)表于 2025-3-29 12:11:31 | 只看該作者
47#
發(fā)表于 2025-3-29 16:25:32 | 只看該作者
48#
發(fā)表于 2025-3-29 19:52:40 | 只看該作者
Vardenafil Clinical Trials Experience,ostheses, as first-line therapy in the majority of men seeking treatment for ED. The first of these PDE5 inhibitors was sildenafil (Viagra?). In spite of the benefits of sildenafil, its ocular effect, which manifests as dose-related changes in blue-tinted vision in some patients, reflects its weak inhibition of PDE6 and lack of selectivity.
49#
發(fā)表于 2025-3-30 03:37:54 | 只看該作者
Is Diabetic Erectile Dysfunction More Difficult to Treat?,ed by ED, compared with approx 50% in an unselected population in the Massachusetts Aging Male Survey (.,.). In another cohort of patients who had type 1 diabetes for at least 10 yr, ED was reported in 1.1% of men aged 21 to 30 yr, 55% of men aged 50 to 60 yr, and 75% of men older than 60 yr (.).
50#
發(fā)表于 2025-3-30 06:29:39 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-9 10:15
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
连云港市| 会昌县| 衡阳市| 敖汉旗| 蒲江县| 青铜峡市| 鹤庆县| 镇平县| 临沭县| 关岭| 临高县| 虎林市| 伊宁县| 平舆县| 广平县| 奉节县| 襄垣县| 巴塘县| 昔阳县| 新化县| 景宁| 太和县| 高雄县| 柳江县| 沙雅县| 淮北市| 施甸县| 和静县| 石柱| 柏乡县| 泗洪县| 舟山市| 泸溪县| 垦利县| 盐津县| 贞丰县| 济源市| 分宜县| 阳朔县| 修水县| 宣城市|